# Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease

> **NCT07483372** · PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 3 (estimated)

## Conditions studied

- Resistant Arterial Hypertension
- Chronic Kidney Disease (Stage 3-4)

## Interventions

- **DRUG:** SC101

## Key facts

- **NCT ID:** NCT07483372
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483372, "Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07483372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*